Abstract:Nonclinical QTc studies can augment clinical QTc assessments in regulatory submissions provided they are of sufficient quality and sensitivity. Both the statistical performance and species translation play a role in determining the sensitivity of the model.The current analyses examine the effects of dofetilide or vehicle on the QT interval in nonhuman primate (NHP; n = 16) using a one-step estimated marginal means method where both treatment and animal ID are used in regression models to avoid a separate rate correction step, in comparison to other commonly utilized methods. The doses of dofetilide were chosen to span a threshold dose with exposure only just exceeding the concentration associated with 10 ms QTc prolongation in man, to a dose where exposures exceed the Emax for QTc prolongation. The primary objective was an evaluation of which doses and exposures can be detected as eliciting a statistically significant change in QTc.A group size of 8 for cross-over analysis was insufficient to detect, as statistically significant, the effects of the threshold dose of 0.01 mg/kg dofetilide using common correction and statistical analysis methods and hourly time intervals. Higher doses were all detected as causing a statistically significant effect using the same techniques. The 'One-Step' method was able to detect as statistically significant effects at all doses of dofetilide across a wide range of time and exposure. There were also temporal differences between the mean effects observed using the common and 'One-Step' methods. Preliminary concentration-QTc assessment suggests a higher maximum prolongation in concentration QTc with the 'One-Step' method. Furthermore, this analysis suggests that at exposures associated with a 10 ms QTc prolongation in man a 10 ms prolongation is also observed in NHP. The observed ED 50 concentration (0.85 ng/ml unbound) is close to that described in man (0.98 ng/ml).These analyses demonstrate the statistical sensitivity of the 'One-Step' method of QTc assessment in NHP. The pharmacological sensitivity was also demonstrated and a detection threshold of 10 ms was consistent in terms of exposure between NHP and man. Overall, QTc assessment using the 'One-Step' method in NHP is a robust and sensitive model to supplement clinical QTc assessment.

Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes

Phase 2 Early Afterdepolarization As A Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-Qt Syndrome - Direct Evidence from Intracellular Recordings in the Intact Left Ventricular Wall

Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.

Preclinical Assessment of Drug-Induced Proarrhythmias: Role of the Arterially Perfused Rabbit Left Ventricular Wedge Preparation

Assessment of Drug-Induced Proarrhythmia: the Importance of Study Design in the Rabbit Left Ventricular Wedge Model.

[Calmodulin Antagonist Inhibits Torsade De Pointes Induced by D-Sotalol in an Isolated Rabbit Heart Model].

Electrophysiologic Features of Torsades De Pointes:

Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation

Modulation of the Late Sodium Current by ATX-II and Ranolazine Affects the Reverse Use-Dependence and Proarrhythmic Liability of IKrblockade

D-sotalol Induced Torsade De Pointes in Isolated Rabbit Heart

Mechanisms underlying spontaneous termination of Torsade de Pointes in an experimental model of long QT syndrome

Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone

Characterization of electropharmacological profile of an anti-atrial fibrillatory drug vernakalant along with potential risk toward torsade de pointes: Translational studies using isoflurane-anesthetized dogs and isolated rat aortic preparations

Effect of Epicardial or Biventricular Pacing to Prolong QT Interval and Increase Transmural Dispersion of Repolarization: Does Resynchronization Therapy Pose a Risk for Patients Predisposed to Long QT or Torsade De Pointes?

Antiarrhythmic Peptide AAP 10 Prevents Ventricular Arrhythmia in Rabbit LQT 2 Model

Demonstrating the statistical and pharmacological sensitivity of nonclinical QTc analysis using a dofetilide dose–response in nonhuman primates

Mechanisms of torsades de pointes: an update

Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium

Mexiletine Prevents Recurrent Torsades De Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures

Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo